[Revisiting the therapeutic concept of a mineralocorticoid receptor antagonist - focusing on resistant hypertension and chronic renal failure].
kikkawa.kohei@mg.mt-pharma.co.jp
Kohei
K
Kikkawa
D000818:Animals; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology; D008019:Life Style; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D051381:Rats; D013148:Spironolactone / Q000627:therapeutic use*
D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone